Skip to main content
Journal cover image

Amiodarone use in patients listed for heart transplant is associated with increased 1-year post-transplant mortality.

Publication ,  Journal Article
Cooper, LB; Mentz, RJ; Edwards, LB; Wilk, AR; Rogers, JG; Patel, CB; Milano, CA; Hernandez, AF; Stehlik, J; Lund, LH
Published in: J Heart Lung Transplant
February 2017

BACKGROUND: Pre-transplant amiodarone use has been postulated as a risk factor for morbidity and mortality after orthotopic heart transplantation (OHT). We assessed pre-OHT amiodarone use and tested the hypothesis that it is associated with impaired post-OHT outcomes. METHODS: We performed a retrospective cohort analysis of adult OHT recipients from the registry of the International Society for Heart and Lung Transplantation (ISHLT). All patients had been transplanted between 2005 and 2013 and were stratified by pre-OHT amiodarone use. We derived propensity scores using logistic regression with amiodarone use as the dependent variable, and assessed the associations between amiodarone use and outcomes with Kaplan-Meier analysis after matching patients 1:1 based on propensity score, and with Cox regression with adjustment for propensity score. RESULTS: Of the 14,944 OHT patients in the study cohort, 32% (N = 4,752) received pre-OHT amiodarone. Amiodarone use was higher in recent years (29% in 2005 to 2007, 32% in 2008 to 2010, 35% in 2011 to 2013). Amiodarone-treated patients were older and more frequently had a history of sudden cardiac death (27% vs 13%) and pre-OHT mechanical circulatory support. Key donor characteristics and allograft ischemia times were similar between groups. In propensity-matched analyses, amiodarone-treated patients had higher rates of cardiac reoperation (15% vs 13%) and permanent pacemaker (5% vs 3%) after OHT and before discharge. Amiodarone-treated patients also had higher 1-year mortality (hazard ratio 1.15, 95% confidence interval 1.02 to 1.30), but the risks of early graft failure, retransplantation and rehospitalization were similar between groups. CONCLUSIONS: Amiodarone use before OHT was independently associated with increased 1-year mortality. The need for amiodarone therapy should be carefully and continuously assessed in patients awaiting OHT.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Heart Lung Transplant

DOI

EISSN

1557-3117

Publication Date

February 2017

Volume

36

Issue

2

Start / End Page

202 / 210

Location

United States

Related Subject Headings

  • Waiting Lists
  • Survival Analysis
  • Surgery
  • Risk Assessment
  • Retrospective Studies
  • Registries
  • Proportional Hazards Models
  • Propensity Score
  • Prognosis
  • Postoperative Complications
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Cooper, L. B., Mentz, R. J., Edwards, L. B., Wilk, A. R., Rogers, J. G., Patel, C. B., … Lund, L. H. (2017). Amiodarone use in patients listed for heart transplant is associated with increased 1-year post-transplant mortality. J Heart Lung Transplant, 36(2), 202–210. https://doi.org/10.1016/j.healun.2016.07.009
Cooper, Lauren B., Robert J. Mentz, Leah B. Edwards, Amber R. Wilk, Joseph G. Rogers, Chetan B. Patel, Carmelo A. Milano, Adrian F. Hernandez, Josef Stehlik, and Lars H. Lund. “Amiodarone use in patients listed for heart transplant is associated with increased 1-year post-transplant mortality.J Heart Lung Transplant 36, no. 2 (February 2017): 202–10. https://doi.org/10.1016/j.healun.2016.07.009.
Cooper LB, Mentz RJ, Edwards LB, Wilk AR, Rogers JG, Patel CB, et al. Amiodarone use in patients listed for heart transplant is associated with increased 1-year post-transplant mortality. J Heart Lung Transplant. 2017 Feb;36(2):202–10.
Cooper, Lauren B., et al. “Amiodarone use in patients listed for heart transplant is associated with increased 1-year post-transplant mortality.J Heart Lung Transplant, vol. 36, no. 2, Feb. 2017, pp. 202–10. Pubmed, doi:10.1016/j.healun.2016.07.009.
Cooper LB, Mentz RJ, Edwards LB, Wilk AR, Rogers JG, Patel CB, Milano CA, Hernandez AF, Stehlik J, Lund LH. Amiodarone use in patients listed for heart transplant is associated with increased 1-year post-transplant mortality. J Heart Lung Transplant. 2017 Feb;36(2):202–210.
Journal cover image

Published In

J Heart Lung Transplant

DOI

EISSN

1557-3117

Publication Date

February 2017

Volume

36

Issue

2

Start / End Page

202 / 210

Location

United States

Related Subject Headings

  • Waiting Lists
  • Survival Analysis
  • Surgery
  • Risk Assessment
  • Retrospective Studies
  • Registries
  • Proportional Hazards Models
  • Propensity Score
  • Prognosis
  • Postoperative Complications